Abogen Biosciences Appoints Song Ziyi as Chief Financial Officer Amid IPO Filing
Abogen
Nucleic Acid Drug Developer
Recently, Abogen Biosciences Co., Ltd. (hereinafter referred to as“Abogen”）Announcement: Appointment of Ms. Song Zi Yi as Chief Financial Officer`, leading the finance, legal, and investor relations teams, fully responsible for the company's financial strategy and management, promoting the overall operational efficiency and capital management capabilities of the company.`
Ms. Song Zi Yi has nearly18Years of experience in investment banking, investment management, corporate investment and financing, and strategy-related work, with rich professional expertise in the healthcare industry and capital markets. Before joining Abogen, Ms. Song Zi Yi worked at Immune-Onc (1541.HK) as Chief Financial Officer and Executive Director, leading and overseeing the company's financing, IPO, financial transactions, and financial strategy. Prior to this, Ms. Song Zi Yi served as2006Since the year, he has held key positions at Merrill Lynch (now BofA Securities), UBS, and CLSA中信里昂, with extensive professional experience in capital markets, including IPOs, financing, and mergers and acquisitions, during which he was responsible for completing50Multiple capital market transactions, later serving as the healthcare investment lead for the Greater Bay Area Fund.
Ms. Song Zi Yi holds a Bachelor’s degree in Mathematics and Economics from the University of Chicago, USA, and a Master’s degree in Medicine from the University of Hong Kong.
"Very excited to join Abogen at this critical stage of its development as the Chief Financial Officer, experiencing and witnessing the company's thrilling growth journey. Abogen possesses internationally leading...mRNATechnology and delivery platforms, with their robust platform-based technical barriers, have tremendous development potential across numerous therapeutic fields.mRNAThe development and application of the platform in the field of large-scale infectious disease prevention and control, with its efficient and safe protection and proven technology, has a high degree of development certainty and a vast market space; in the field of oncology, especially in conjunction withAIThe integration with automation technology can significantly enhance the efficiency of research and development as well as production, and is expected to bring entirely new, disruptive approaches to cancer treatment. I will fully support Dr. Yingbo, working closely with the team, collaborating wholeheartedly, and exploring and unleashing the full potential across multiple therapeutic fields.RNAThe application value of the platform opens up tremendous market potential.
"We are delighted to invite Ms. Song Zi Yi to join Abogen.Ms. Song Zi Yi has rich experience in capital market operations., ExcellenceExcellent financial management skills and a diversified academic background.Currently, Abogen's platform technologyContinuously consolidated, achieving breakthrough progress in the development of multiple underlying technologies, and is gradually applying the experience from COVID-19 products to areas such as infectious disease vaccines and oncology products, recently obtaining very positive clinical POs.C data once again fully validates the company's platform technology.During this critical period, Ms. Song Zi Yi'sThe addition will further enhance the company's financial management and capital operation capabilities, and will also provide critical support for achieving the company’s overall strategy and ensuring efficient and compliant operations.We look forward to working together with Ms. Song Ziyi to elevate Abogen to a new level.。
AbogenAbogen Biosciences Co., Ltd. (referred to as Abogen) is a company focused on messenger ribonucleic acid (mRNA) An innovative biopharmaceutical company focused on drug research and development. The company possesses industry-leading, proprietary intellectual property.mRNAAnd the nanotechnology delivery platform, is one of the few in China with complete value chain capabilities.mRNAPharmaceutical R&D enterprises, covering frommRNADesign, formulation development, and large-scale production. The company has established a rich product pipeline, covering includingmRNAIncluding the prevention and treatment of infectious diseases such as COVID-19 vaccines, tumor immunology, protein replacement therapy, and other fields.2022Year9Month, Abogen's novel coronavirusmRNAVaccineARCoVGranted Emergency Use Authorization in Indonesia, becoming the first self-developed Chinese product to receive overseas marketing approval.mRNAVaccine.
E.N.D
Previous article recommendations:
A Comprehensive Guide to the Specific Differences Between CXO, CRO, CMO, CDMO, and CSO
Huace Biomann's First TIL Cell Therapy HS-IT101 Completes First Dosing in Phase I Clinical Trial
Synthetic biology ranks first!
Fosun Pharma Subsidiary’s NK Cell Therapy GCK-01 Approved for Clinical Trials
First in China, Yaotang Biotech's In Vivo Gene Editing Drug YOLT-201 Approved for Clinical Trials
MaioBio R&D Center Officially Launched!
CARsgen Pharma's BCMA CAR-T Product Approved for Marketing in China
Six Companies in China Complete New Round of Financing, Focusing on Cell and Gene Therapy Fields
Manufacturing Process and Challenges of Universal CAR-T
Zhongmou Medical Is About to Launch Gene Therapy Clinical Trials for Advanced Retinitis Pigmentosa
First AAV Gene Therapy for Hemophilia A Falls Far Short of Sales Expectations Last Year
The World's First AAV Gene Therapy for Autism Approved for Clinical Trials
CDE Releases "Technical Guidelines for Non-Clinical Research of Human Stem Cell Products"
CRISPR/Cas9 Gene Editing Therapy Receives FDA Approval for Treating β-Thalassemia